Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships.
Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations.
Materials And Methods: Literature review and consensus of expert opinion.
Summary Recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.maturitas.2021.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prioritising gynaecological care in post-haematopoietic stem cell transplant patients.
BMJ Case Rep
January 2025
Reproductive Medicine and Surgery, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India.
An adolescent girl with acute myeloid leukaemia underwent chemotherapy followed by haematopoietic stem cell transplantation (HSCT). Post-HSCT, she developed oral chronic graft-versus-host disease (cGvHD), which was successfully treated. Twenty months later, she was referred to the gynaecology department for evaluation of secondary amenorrhoea.
View Article and Find Full Text PDFVulvodynia - A contemporary understanding and practical approach in primary care settings.
Malays Fam Physician
December 2024
MCGP, FRCOG, Department of Obstetrics and Gynaecology, IMU University, Clinical Campus, Jalan Rasah, Bukit Rasah, Seremban, Negeri Sembilan, Malaysia.
Vulvodynia manifests as persistent vulvar pain, affecting both sexual well-being and overall quality of life. While the precise cause remains elusive, various multifaceted predisposing and precipitating factors have been identified. Neurobiological and psychosocial elements contribute to a better understanding of the management of this complex disorder.
View Article and Find Full Text PDFBladder Outlet Obstruction Due to Recurrent Complete Labial Fusion in Postmenopausal Woman-Case Report.
Diagnostics (Basel)
November 2024
Department of Surgery II-Orthopedics and Traumatology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Background: Labial fusion is a rare condition typically observed in prepubescent girls, but it can also occur in postmenopausal women due to estrogen deficiency.
Methods: Our case report presents a unique instance of recurrent complete labial fusion causing bladder outlet obstruction in a postmenopausal woman.
Results: The 84-year-old patient presented with dysuria and intermittent urine leakage.
Phytoestrogens as Natural Anti-Aging Solutions for Enhanced Collagen Synthesis in Skin.
J Cosmet Dermatol
December 2024
Global Research and Development, Oriflame Cosmetics, Stockholm, Sweden.
Background: The dermal extracellular matrix (ECM) is a dynamic scaffold composed mainly of proteins, with collagen as the key structural component providing resilience and support to the skin. Post-menopause, declining estrogen levels lead to a significant reduction in skin health, notably a 30% decrease in collagen types I and III within 5 years.
Aim: To discover natural extracts that stimulate collagen production.
Compatibility of 17-α-Estradiol, Betamethasone, Finasteride, Melatonin, Prednicarbate, and Spironolactone in TrichoFoam™ - a Foaming Vehicle for Personalized Alopecia Treatments.
Int J Pharm Compd
December 2024
Fagron BV, Rotterdam, The Netherlands.
Objective: This study evaluates the physicochemical compatibility of six active pharmaceutical ingredients (APIs) - 17-a-estradiol, betamethasone, finasteride, melatonin, prednicarbate, and spironolactone - in TrichoFoam™, a foaming vehicle designed for personalized alopecia treatments.
Background: Alopecia, a condition impacting around 2% of the global population, can benefit from more effective and patient-friendly treatments. TrichoFoam™ represents a personalized medicine approach that utilizes a foam base to enhance the delivery and efficacy of topical treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!